Related Experiment Video
Updated: Jul 20, 2026

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Present and future of lung cancer vaccines
Luis E Raez1, Joseph D Rosenblatt, Eckhard R Podack
1Thoracic Oncology Group, Sylvester Comprehensive Cancer Center, Division of Hematology-Oncology, University of Miami School of Medicine, 1475 NW 12 Avenue, Miami, FL 33136, USA. LRaez@med.miami.edu
Abstract:
New approaches are needed to improve the current treatment of lung cancer. Inducing an immune response against lung tumour cells with vaccines represents an attractive therapy. However, lung tumours had not been considered good targets for vaccine therapy and, therefore, immune approaches have not been studied extensively in this setting. Current experimental strategies for antitumour vaccines include the generation of active immune responses against specific tumour antigens. Understanding the mechanisms of antitumour immunity and identifying relevant tumour-specific antigens will probably improve therapeutic strategies and provide avenues for the future of lung cancer therapy. There have been a number of preclinical immunotherapy trials suggesting activity, and a smaller number of human clinical trials using various vaccines in lung cancer. Initial data from these trials have shown preliminary evidence of induction of immune responses and suggest clinical activity. This paper reviews some of the most important developments in vaccines for lung cancer.
Insights
Lung cancer vaccines are an emerging immunotherapy approach. Early trials show promising immune responses and potential clinical activity, offering new avenues for lung cancer treatment.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Lung cancer treatment requires novel approaches.
- Vaccine therapy to induce immune responses against lung tumor cells is a promising strategy.
- Lung tumors have historically been challenging targets for immunotherapy.
Purpose of the Study:
- To review recent developments in lung cancer vaccines.
- To highlight the potential of immunotherapy in lung cancer treatment.
- To discuss the identification of tumor-specific antigens for improved vaccine efficacy.
Main Methods:
- Review of preclinical and clinical trials of lung cancer vaccines.
- Analysis of immune response induction in patients.
- Evaluation of preliminary clinical activity data.
Main Results:
- Preclinical trials suggest immunotherapy has activity in lung cancer.
- Clinical trials demonstrate the induction of immune responses.
- Preliminary data indicate potential clinical activity of lung cancer vaccines.
Conclusions:
- Lung cancer vaccines represent an attractive therapeutic strategy.
- Further research into tumor antigens and immune mechanisms is crucial.
- Vaccine-based immunotherapy holds promise for future lung cancer therapy.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Microorganisms in Medicine and Therapeutics
Tumor Immunotherapy
Cancer Prevention
Some...
